Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy

Annual Review of Pharmacology and Toxicology

Volumn 49, Issue , 2009, Pages 223-241

  Shangary, Sanjeev ^a,b   Wang, Shaomeng ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Oncoprotein HDM2; p53 reactivation; Small molecule inhibitors of HDM2; Tumor suppressor p53

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 7 [ANILINO(PHENYL)METHYL] 2 METHYL 8 QUINOLINOL; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORAMBUCIL; CYTARABINE; DOXORUBICIN; FLUDARABINE; MI 219; MI 63; NSC 66811; NUTLIN 1; NUTLIN 2; NUTLIN 3; PROTEIN MDM2; PROTEIN MDM2 SMALL MOLECULE INHIBITOR; PROTEIN MDMX; PROTEIN P53; TDP 521252; TDP 665759; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PIPERAZINE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CELL CYCLE ARREST; CELL DEATH; CELL MEMBRANE PERMEABILITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; OSTEOSARCOMA; PHARMACOPHORE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR SUPPRESSOR GENE; ANIMAL; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DESIGN; METABOLISM; NEOPLASM; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; IMIDAZOLES; NEOPLASMS; NUCLEAR PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65249100143     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.48.113006.094723     Document Type: Review

References (102)

1. Fridman JS, Lowe SW. 2003. Control of apoptosis by p53. Oncogene 22:9030-40
2. Hainaut P, Hollstein M. 2000. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77:81-137
3. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-10
4. Vousden KH, Lu X. 2002. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2:594-604
5. Shangary S, Wang S. 2008. Targeting the MDM2-p53 interaction for cancer therapy. Clin. Cancer Res. 14:5318-24
6. Lane DP, Crawford LV. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-63
7. Linzer DI, Levine AJ. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52
8. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. 1979. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 76:2420-24
9. Finlay CA, Hinds PW, Levine AJ. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-93
10. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. 1990. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-49
11. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-38
12. Feki A, Irminger-Finger I. 2004. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 52:103-16
13. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-45
14. Fakharzadeh SS, Trusko SP, George DL. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565-69
15. Fakharzadeh SS, Rosenblum-Vos L, Murphy M, Hoffman EK, George DL. 1993. Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics 15:283-90
16. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602
17. Oliner JD, Kinzler KW,Meltzer PS, George DL, Vogelstein B. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83
18. Zhou M, Gu L, Abshire TC, Homans A, Billett AL, et al. 2000. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 14:61-67
19. Rayburn E, Zhang R, He J,Wang H. 2005.MDM2and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets 5:27-41
20. Momand J, Jung D,Wilczynski S, Niland J. 1998. The MDM2 gene amplification database. Nucleic Acids Res. 26:3453-59
21. Gunther T, Schneider-Stock R, Hackel C, Kasper HU, Pross M, et al. 2000. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod. Pathol. 13:621-26
22. Bond GL, Hu W, Levine AJ. 2005. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5:3-8
23. Capoulade C, Bressac-de Paillerets B, Lefrere I, Ronsin M, Feunteun J, et al. 1998. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 16:1603-10
24. Momand J,Wu HH, Dasgupta G. 2000. MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15-29
25. Ganguli G, Abecassis J, Wasylyk B. 2000. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J. 19:5135-47
26. Kemp CJ, Donehower LA, Bradley A, Balmain A. 1993. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74:813-22
27. Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, et al. 2000. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am. J. Pathol. 157:2151-59
28. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445:661-65
29. Martins CP, Brown-Swigart L, Evan GI. 2006. Modeling the th erapeutic efficacy of p53 restoration in tumors. Cell 127:1323-34
30. Xue W, Zender L, Miething C, Dickins RA, Hernando E, et al. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656-60
31. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, et al. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8:282-88
32. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, et al. 2004. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10:1321-28
33. Vassilev LT. 2007. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13:23-31
34. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-48
35. Wiman KG. 2006. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13:921-26
36. Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S, Ding Y, et al. 2005. Structure-based design of potent nonpeptide MDM2 inhibitors. J. Am. Chem. Soc. 127:10130-31
37. Shangary S, Qin D, McEachern D, Liu M, Miller RS, et al. 2008. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. USA 105:3933-38
38. Freedman DA,Wu L, Levine AJ. 1999. Functions of the MDM2 oncoprotein. Cell Mol. Life Sci. 55:96-107
39. Juven-Gershon T, Oren M. 1999. Mdm2: the ups and downs. Mol. Med. 5:71-83
40. Wu X, Bayle JH, Olson D, Levine AJ. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-32
41. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-8
42. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-6
43. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME. 2003. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell Biol. 23:462-72
44. Chen J, Marechal V, Levine AJ. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13:4107-14
45. Picksley SM, Vojtesek B, Sparks A, Lane DP. 1994. Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9:2523-29
46. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-53
47. Vassilev LT. 2004. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3:419-21
48. Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, et al. 2006. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 49:3432-35
49. Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, et al. 2008. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol. Cancer Ther. 7:1533-42
50. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, et al. 2005. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 48:909-12
51. Parks DJ, Lafrance LV, Calvo RR, Milkiewicz KL, Gupta V, et al. 2005. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 15:765-70
52. Koblish HK, Zhao S, Franks CF, Donatelli RR, Tominovich RM, et al. 2006. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther. 5:160-69
53. Yin H, Lee GI, Park HS, Payne GA, Rodriguez JM, et al. 2005. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew. Chem. Int. Ed. Engl. 44:2704-7
54. Chen L, Yin H, Farooqi B, Sebti S, Hamilton AD, Chen J. 2005. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53. Mol. Cancer Ther. 4:1019-25
55. Lu Y, Nikolovska-Coleska Z, Fang X, Gao W, Shangary S, et al. 2006. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J. Med. Chem. 49:3759-62
56. Stoll R, Renner C, Hansen S, Palme S, Klein C, et al. 2001. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40:336-44
57. Galatin PS, Abraham DJ. 2004. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J. Med. Chem. 47:4163-65
58. Lin J, Chen J, Elenbaas B, Levine AJ. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1235-46
59. Bottger V, Bottger A, Howard SF, Picksley SM, Chene P, et al. 1996. Identification of novel mdm2 binding peptides by phage display. Oncogene 13:2141-47
60. Garcia-Echeverria C, Chene P, Blommers MJ, Furet P. 2000. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 43:3205-8
61. Milne GW, Nicklaus MC, Driscoll JS, Wang S, Zaharevitz D. 1994. National Cancer Institute Drug Information System 3D database. J. Chem. Inf. Comput. Sci. 34:1219-24
62. Voigt JH, Bienfait B, Wang S, Nicklaus MC. 2001. Comparison of the NCI open database with seven large chemical structural databases. J. Chem. Inf. Comput. Sci. 41:702-12
63. Jones G, Willett P, Glen RC, Leach AR, Taylor R. 1997. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267:727-48
64. Verdonk ML, Cole JC, Hartshorn MJ,Murray CW, Taylor RD. 2003. Improved protein-ligand docking using GOLD. Proteins 52:609-23
65. Eldridge MD,Murray CW, Auton TR, Paolini GV, Mee RP. 1997. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des. 11:425-45
66. Wang R, Lai L,Wang W. 2002. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J. Comput. Aided Mol. Des. 16:11-26
67. Bowman AL, Nikolovska-Coleska Z, Zhong H,Wang S, Carlson HA. 2007. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J. Am. Chem. Soc. 129:12809-14
68. Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD. 2002. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J. Am. Chem. Soc. 124:11838-39
69. Go ML,Wu X, Liu XL. 2005. Chalcones: an update on cytotoxic and chemoprotective properties. Curr. Med. Chem. 12:481-99
70. Leonard K, Marugan JJ, Raboisson P, Calvo R, Gushue JM, et al. 2006. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorg. Med. Chem. Lett. 16:3463-68
71. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. 2006. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J. Biol. Chem. 281:33030-35
72. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, et al. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature 444:61-66
73. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. 2006. Levels of Hdm X expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 66:3169-76
74. Wade M, Rodewald LW, Espinosa JM, Wahl GM. 2008. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle 7:1973-82
75. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. 2006. Hdmx modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 281:33036-44
76. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, et al. 2004. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 279:53015-22
77. Cheok CF, Dey A, Lane DP. 2007. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlininduced apoptosis: a potent drug combination. Mol. Cancer Res. 5:1133-45
78. Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N. 2008. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage-independent p53 phosphorylation in mantle cell lymphoma. Clin. Cancer Res. 14:5416-25
79. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, et al. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169-74
80. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, et al. 1997. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1:3-11
81. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, et al. 2006. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 103:1888-93
82. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. 2006. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10:501-14
83. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, et al. 2005. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106:3150-59
84. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, et al. 2007. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ. Res. 100:61-69
85. Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, et al. 2006. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3a in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107:4122-29
86. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. 2006. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108:993-1000
87. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, et al. 2006.MDM2antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107:4109-14
88. Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, et al. 2007. Comprehensive biomarker and genomic analysis identifies P53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111:1584-93
89. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, et al. 2005. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106:3609-17
90. Kastan MB. 2007. Our cells get stressed too! Implications for human disease. Blood Cells Mol. Dis. 39: 148-50
91. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. 2005. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 65:1918-24
92. Kranz D, Dobbelstein M. 2006. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res. 66:10274-80
93. Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, Van Der Eb AJ, et al. 1999. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18:189-99
94. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, et al. 1996. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 15:5349-57
95. Jackson MW, Berberich SJ. 2000. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell Biol. 20:1001-7
96. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. 1999. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447:5-9
97. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, et al. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29:92-95
98. Migliorini D, Lazzerini Denchi E, Danovi D, Jochemsen A, et al. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell Biol. 22:5527-38
99. Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, et al. 2007. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 6:2386-92
100. Sarek G, Kurki S, Enback J, Iotzova G, Haas J, et al. 2007. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J. Clin. Invest. 117:1019-28
101. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-49
102. Potten CS,Wilson JW, Booth C. 1997. Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem. Cells 15:82-93